Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Columbia Labs

This article was originally published in The Tan Sheet

Executive Summary

Net sales fell 62.5% to $2.7 mil. for the second quarter, leading to a net loss of $1.2 mil. compared to net income of $1.2 mil. in the year-ago period, the Aventura, Fla.-based firm announces Aug. 10. The company attributes the poor performance to low sales of its Rx drug Crinone due to a switch in marketing partners. Sales of the Advantage-S spermicide were not listed; a recent Joint U.N. Program on HIV/AIDS showed the nonoxynol-9 gel is not effective at preventing HIV. Columbia has disputed the results and demanded an outside review (1"The Tan Sheet" June 19, p. 4)

You may also be interested in...

Columbia Labs Advantage-S Additional HIV Prevention Trials Unlikely

"It will be very difficult to conduct another study" on Advantage-S (nonoxynol-9) and HIV prevention after a Joint U.N. Program on HIV/AIDS trial produced negative results, Columbia Labs Chairman and CEO William Bologna asserted during a June 12 conference call.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts